Financials data is unavailable for this security.
View more
Year on year Immuno-Biological Laboratories Co Ltd had relatively flat revenues (794.62m to 816.70m), though the company grew net income from a loss of 289.73m to a gain of 186.69m. A reduction in the selling, general and administrative costs as a percentage of sales from 36.33% to 34.41% was a component in the net income growth despite flat revenues.
Gross margin | 65.48% |
---|---|
Net profit margin | 26.11% |
Operating margin | 17.87% |
Return on assets | 14.57% |
---|---|
Return on equity | 18.86% |
Return on investment | 17.43% |
More ▼
Cash flow in JPYView more
In 2024, Immuno-Biological Laboratories Co Ltd increased its cash reserves by 20.10%, or 112.97m. The company earned 133.78m from its operations for a Cash Flow Margin of 16.38%. In addition the company generated 992.00k cash from financing while 24.50m was spent on investing.
Cash flow per share | 5.76 |
---|---|
Price/Cash flow per share | 79.72 |
Book value per share | 141.37 |
---|---|
Tangible book value per share | 141.14 |
More ▼
Balance sheet in JPYView more
Current ratio | 4.75 |
---|---|
Quick ratio | 3.58 |
Total debt/total equity | 0.1823 |
---|---|
Total debt/total capital | 0.1542 |
More ▼